184 related articles for article (PubMed ID: 30454022)
1. Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report.
Myro AZ; Bjerke G; Zarnovicky S; Holmøy T
BMC Pharmacol Toxicol; 2018 Nov; 19(1):75. PubMed ID: 30454022
[TBL] [Abstract][Full Text] [Related]
2. Diffuse Alveolar haemorrhage: a fatal complication after alemtuzumab induction therapy in renal transplantation.
Tahir W; Hakeem A; Baker R; Ahmad N
Transplant Proc; 2015; 47(1):151-4. PubMed ID: 25645795
[TBL] [Abstract][Full Text] [Related]
3. Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.
Lapucci C; Gualandi F; Mikulska M; Palmeri S; Mancardi G; Uccelli A; Laroni A
Mult Scler Relat Disord; 2018 Nov; 26():52-54. PubMed ID: 30223229
[TBL] [Abstract][Full Text] [Related]
4. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
[TBL] [Abstract][Full Text] [Related]
5. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.
Yann K; Jackson F; Sharaf N; Mihalova T; Talbot P; Rog D; Pace A
Mult Scler Relat Disord; 2017 May; 14():1-3. PubMed ID: 28619423
[TBL] [Abstract][Full Text] [Related]
6. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
[TBL] [Abstract][Full Text] [Related]
7. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.
Canham LJW; Manara A; Fawcett J; Rolinski M; Mortimer A; Inglis KEA; Cottrell DA
Mult Scler Relat Disord; 2018 Aug; 24():38-41. PubMed ID: 29885597
[TBL] [Abstract][Full Text] [Related]
8. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
Whiteside D; Barth S; Datta A; Trip SA
Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
di Ioia M; Farina D; di Tommaso V; Travaglini D; Pietrolongo E; Onofrj M; de Luca G
Mult Scler; 2018 May; 24(6):813-815. PubMed ID: 29359617
[TBL] [Abstract][Full Text] [Related]
11. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Obermann M; Ruck T; Pfeuffer S; Baum J; Wiendl H; Meuth SG
Mult Scler; 2016 Aug; 22(9):1235-41. PubMed ID: 26980848
[TBL] [Abstract][Full Text] [Related]
14. Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab.
Croteau D; Flowers C; Kulick CG; Brinker A; Kortepeter CM
Neurology; 2018 May; 90(18):e1548-e1552. PubMed ID: 29602912
[TBL] [Abstract][Full Text] [Related]
15. Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration.
Hoffman BM; Zeid NA; Alam U; Caress JB
Mult Scler Relat Disord; 2019 Jan; 27():131-132. PubMed ID: 30384197
[TBL] [Abstract][Full Text] [Related]
16. Acute severe hepatitis with alemtuzumab and rechallenge after a year.
Beattie W; Yan B; Sood S
J Clin Neurosci; 2019 Feb; 60():158-160. PubMed ID: 30348589
[TBL] [Abstract][Full Text] [Related]
17. Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis.
Šega-Jazbec S; Barun B; Horvat Ledinek A; Fabekovac V; Krbot Skorić M; Habek M
Mult Scler Relat Disord; 2017 Oct; 17():151-153. PubMed ID: 29055450
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune storm following alemtuzumab.
Chan C; Beauchemin P; Sayao AL; Carruthers M
BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35760506
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab for the treatment of multiple sclerosis.
Evan JR; Bozkurt SB; Thomas NC; Bagnato F
Expert Opin Biol Ther; 2018 Mar; 18(3):323-334. PubMed ID: 29309202
[TBL] [Abstract][Full Text] [Related]
20. Diffuse alveolar hemorrhage in limited cutaneous systemic sclerosis with positive perinuclear antineutrophil cytoplasmic antibodies.
Vázquez-Del Mercado M; Mendoza-Topete A; Best-Aguilera CR; Garcia-De La Torre I
J Rheumatol; 1996 Oct; 23(10):1821-3. PubMed ID: 8895168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]